AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
Log in

ASX:IMMImmutep Stock Price, Forecast & News

A$0.15
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.15
Now: A$0.15
A$0.15
50-Day Range
A$0.15
MA: A$0.15
A$0.15
52-Week Range
A$0.10
Now: A$0.15
A$0.50
Volume2.15 million shs
Average VolumeN/A
Market Capitalization$58.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8315 7003

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.95 million
Cash FlowA$0.05 per share
Book ValueA$0.07 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$58.32 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Immutep (ASX:IMM) Frequently Asked Questions

How has Immutep's stock been impacted by COVID-19 (Coronavirus)?

Immutep's stock was trading at A$0.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMM shares have decreased by 55.9% and is now trading at A$0.15. View which stocks have been most impacted by Coronavirus.

How were Immutep's earnings last quarter?

Immutep Ltd (ASX:IMM) issued its quarterly earnings results on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. View Immutep's earnings history.

Has Immutep been receiving favorable news coverage?

News coverage about IMM stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Immutep earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Immutep.

Who are some of Immutep's key competitors?

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include ICL Group (ICL), Geron (GERN), Immersion (IMMR), Innovative Industrial Properties (IIPR), Evoke Pharma (EVOK), Enphase Energy (ENPH), DURECT (DRRX), Denali Therapeutics (DNLI), Cynata Therapeutics (CYP) and Yamana Gold (AUY).

Who are Immutep's key executives?

Immutep's management team includes the following people:
  • Mr. Marc Voigt, Exec. Director, CEO, CFO & Chief Bus. Officer (Age 46)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 42)
  • Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64)
  • Mr. Jay R. Campbell, Chief Bus. Officer and VP of Bus. Devel. & Investor Relations
  • Mr. David Fang, Fin. Director & Assistant Company Sec.

What is Immutep's stock symbol?

Immutep trades on the ASX under the ticker symbol "IMM."

What is Immutep's stock price today?

One share of IMM stock can currently be purchased for approximately A$0.15.

How big of a company is Immutep?

Immutep has a market capitalization of $58.32 million and generates $12.95 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.primabiomed.com.au.

How can I contact Immutep?

The company can be reached via phone at 61 2 8315 7003.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.